| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2024-09-10 18:59:21 UTC |
|---|
| Updated at | 2024-09-10 18:59:22 UTC |
|---|
| NP-MRD ID | NP0334579 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Clopidogrel |
|---|
| Description | Clopidogrel, also known as plavix or isocover, belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids. Clopidogrel is a very strong basic compound (based on its pKa). Within humans, clopidogrel participates in a number of enzymatic reactions. In particular, clopidogrel can be converted into 2-oxoclopidogrel; which is catalyzed by the enzymes cytochrome P450 1A2, cytochrome P450 2B6, and cytochrome P450 2C19. In addition, clopidogrel can be converted into clopidogrel; which is catalyzed by the enzyme multidrug resistance protein 1. Clopidogrel was first documented in 2003 (PMID: 14502454). In humans, clopidogrel is involved in clopidogrel action pathway (PMID: 15976759) (PMID: 16454979) (PMID: 16772608) (PMID: 12595854). |
|---|
| Structure | [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (+)-Clopidogrel | ChEBI | | Clopidogrelum | ChEBI | | Plavix | Kegg | | (+)-(S)-Clopidogrel | HMDB | | (S)-Clopidogrel | HMDB | | Clopidogrel bisulfate | HMDB | | Clopidogrel bisulphate | HMDB | | Isocover | HMDB | | Clopidogrel sandoz | HMDB | | Clopidogrel hydrochloride | HMDB | | BMS Brand 1 OF clopidogrel bisulfate | HMDB | | Clopidogrel napadisilate | HMDB | | Clopidogrel, (+)(S)-isomer | HMDB | | BMS Brand 2 OF clopidogrel bisulfate | HMDB | | Clopidogrel besylate | HMDB | | Iscover | HMDB | | Clopidogrel-mepha | HMDB | | Clopidogrel besilate | HMDB | | Clopidogrel mepha | HMDB |
|
|---|
| Chemical Formula | C16H16ClNO2S |
|---|
| Average Mass | 321.8220 Da |
|---|
| Monoisotopic Mass | 321.05903 Da |
|---|
| IUPAC Name | methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate |
|---|
| Traditional Name | clopidogrel |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl |
|---|
| InChI Identifier | InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1 |
|---|
| InChI Key | GKTWGGQPFAXNFI-HNNXBMFYSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| Not Available | | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | Not Available |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Alpha amino acid esters |
|---|
| Alternative Parents | |
|---|
| Substituents | - Alpha-amino acid ester
- Thienopyridine
- Chlorobenzene
- Halobenzene
- Aralkylamine
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Pyridine
- Benzenoid
- Heteroaromatic compound
- Methyl ester
- Thiophene
- Carboxylic acid ester
- Tertiary amine
- Tertiary aliphatic amine
- Monocarboxylic acid or derivatives
- Azacycle
- Organoheterocyclic compound
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Carbonyl group
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC: Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med. 2005 Jun;145(6):309-15. doi: 10.1016/j.lab.2005.03.010. [PubMed:15976759 ]
- Chen YG, Xu F, Zhang Y, Ji QS, Sun Y, Lu RJ, Li RJ: Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J (Engl). 2006 Jan 5;119(1):32-6. [PubMed:16454979 ]
- Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006 Oct 1;108(7):2244-7. doi: 10.1182/blood-2006-04-013052. Epub 2006 Jun 13. [PubMed:16772608 ]
- Gansera B, Schmidtler F, Spiliopoulos K, Angelis I, Neumaier-Prauser P, Kemkes BM: Urgent or emergent coronary revascularization using bilateral internal thoracic artery after previous clopidogrel antiplatelet therapy. Thorac Cardiovasc Surg. 2003 Aug;51(4):185-9. doi: 10.1055/s-2003-42260. [PubMed:14502454 ]
- Bauriedel G, Skowasch D, Schneider M, Andrie R, Jabs A, Luderitz B: Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. Am Heart J. 2003 Feb;145(2):343-8. doi: 10.1067/mhj.2003.22. [PubMed:12595854 ]
|
|---|